AGM Statement

RNS Number:9258M
Tissue Science Laboratories PLC
30 June 2003

                                                                    30 June 2003



                        Tissue Science Laboratories PLC

                        Result of Annual General Meeting



Tissue Science Laboratories plc, the medical devices company specialising in
human tissue replacement and repair, held its Annual General Meeting on 27 June
2003 at which all resolutions referred to in the Notice of Annual General
Meeting dated 21 May 2003, were passed.

                                     -Ends-

Enquiries:
TSL plc                                                      Tel:      [phone]

Martin Hunt, Chief Executive Officer
David Jennings, Finance Director
MTS Business Communications                                  Tel:      [phone]
Melanie Toyne Sewell



Notes to Editors

Background on TSL

Founded in 1995 with headquarters in Aldershot, Hampshire, TSL has used its
proprietary technology to launch successfully two different formulations of the
product and build a development pipeline that addresses the large and fast
growing surgical implant and woundcare markets. The Company floated in November
2001 and is listed on the Alternative Investment Market.

TSL has a family of products based on the same core technology. Each product has
been adapted, with unique properties, to make it suitable for use in different
applications. PelvicolTM /PermacolTM Surgical Implant (SI) is sold by Bard in
the US and Europe for urology and gynaecology applications; PermacolTM SI
(general surgery) is sold for complex hernia repair in the US and Europe;
PermacolTM SI (ENT, plastic and reconstruction) is sold in Europe for head and
neck applications, with an expected US launch in 2003; PermacolTM Injection
(UBA) is an injectable form of PermacolTM used as a urethral bulking agent to
treat female stress incontinence. Further variations of the sheet and injectable
forms of PermacolTM are being developed for facial augmentation and
reconstruction, and wound therapy applications.

Bard is a trademark of C.R. Bard, Inc. or an affiliate.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGMZGGFVLGRGFZG